Leading-edge medical care through clinical research.
Getting care at AdventHealth Tampa, formerly Florida Hospital Tampa, means getting access to the latest heart care research studies, procedures, and technologies including access to heart treatment clinical trials that aren’t widely available elsewhere.
Following is a list of active studies in which we are currently enrolling patients. If you would like more information about a trial, please call Call813-615-7527 or visit clinicaltrials.gov.
Active Research Trials
CARDIOVASCULAR TRIALS
AEGIS II: InvestigatingCSL112 in Subjects with Acute Coronary Syndrome. Lead: Poliana Desarden
AKI: The purpose of this study is to evaluate the efficacy of post-surgery treatment with ASP1128 in subjects at risk for acute kidney injury (AKI) following CABG and/or valve surgery Lead: Mari Hardy
APPRAISE ATP: Assessment of primary prevention patients receiving an ICD. Lead: Poliana Desarden
BMAD-HF: Benefits of µCor in ambulatory decompensated heart failure. Lead: Juliet Bala
BIOFLOW-VII: Confirming that the clinical performance of the Orsiro stent in a real-world setting is similar to the clinical performance observed for Orsiro in the BIOFLOW-V Investigational Device Exemption pivotal trial. Lead: Juliet Bala
BIO-LIBRA: Analysis of sex and device specific factors on outcomes in patients with non-ischemic cardiomyopathy. Lead: Juliet Bala
CADFEM: Phase signal acquisition system (PSAQ), a medical device system. Lead: Mari Hardy
CONNECT-HF: Optimization through patient and hospital engagement clinical trial for heart failure. Lead: Melanie Stinson
CLOUT: Evaluate real world patient outcomes after treatment of acute and non-acute lower extremity deep vein thrombosis (DVT) with the ClotTriever Thrombectomy System.Lead: Juliet Bala
FROZEN: To establish the safety and effectiveness of the Boston Scientific Cardiac Cryoablation System for treatment of symptomatic, drug refractory, recurrent, paroxysmal atrial fibrillation. Lead: Cynthia Paysor
KNOCOUT PE: Ekosonic registry of the treatment and clinical outcomes of pulmonary embolism. Lead: Juliet Bala
NEUROSCIENCE TRIALS
EP0092: To evaluate the efficacy, safety and tolerability of the 3 selected dose regimens of padsevonil (PSL) administered concomitantly with up to 3 anti-epileptic drugs (AEDs) compared with placebo for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy. Lead: Poliana Desarden
LGS001: Open-label, multi-center study of carisbamate in adult and pediatrics with Lennox-Gastaut Syndrome. Lead: Poliana Desarden
XENON: Randomized trial to evaluate safety, tolerability and efficacy of XEN1101 as adjunctive therapy in focal-onset epilepsy. Lead: Mari Hardy
DIGESTIVE HEALTH TRIALS
ABBVIE M14-234:A Study to Evaluate the Safety and Efficacy of Upadacitinib for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. Lead: Christopher Carr
ABBVIE M14-430: A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib in Subjects with Crohn's Disease. Lead: Christopher Carr
ABBVIE M14-431: A Study of the Efficacy and Safety of Upadacitinib in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy. Lead: Christopher Carr
ABBVIE M14-433: A Study of the Efficacy and Safety of Upadacitinib in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies. Lead: Christopher Carr
ABBVIE M14-533: A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib in Subjects With Ulcerative Colitis. Lead: Christopher Carr
ABBVIE M14-675: A Study of the Efficacy and Safety of Upadacitinib in Participants with Moderately to Severely Active Ulcerative Colitis (U-Accomplish). Lead: Christopher Carr
ABBVIE M16-066: A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065. Lead: Christopher Carr
ABBVIE M16-067: A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants with Moderately to Severely Active Ulcerative Colitis (U-Accomplish). Lead: Christopher Carr
ADMIRE-CD-II: Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease. Lead: Christopher Carr
AURORA: Phase 3 study to evaluate cenicriviroc for treatment of liver fibrosis in patients with NASH.Lead: Christopher Carr
EPIDURAL vs GENERAL: Comparing Epidural Versus General Anesthesia for LESS Cholecystectomies. Lead: Trenton Lippert
GALAXI: A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease. Lead: Christopher Carr
GHPANC-1-001: Determine Function of Antroquinonol in Combination with SOC in First Line Metastatic Pancreatic Cancer. Lead: Christopher Carr
HBOT: Randomized 1:1 pre-operative hyperbaric oxygen therapy (HBOT) vs. no therapy to determine if pre-op HBOT can improve post-operative outcomes. Lead: Trenton Lippert
PANC VOL: Study to determine if length of duodenum and volume of pancreas removed can be used as a predictive factor for the development of post-operative diabetes. Lead: Trenton Lippert
PANOVA-3: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant with Gemcitabine and Nab-paclitaxel. Lead: Trenton Lippert
TAMLAPS: Registry and tissue sample consent specifically for patients scheduled for the TAMLAPS procedure.Lead: Trenton Lippert
TYME-88: A Multi-Center Study of SM-88 in Subjects with Pancreatic Cancer. Lead: Christopher Carr
RHEUMATOLOGY TRIALS
AMG-570/SLE: Determine if AMG 570 could be a useful therapeutic agent in the current treatment landscape where subjects with systemic lupus erythematosus (SLE) have ongoing disease activity despite treatment with standard of care therapies. Lead: Courtney Humiston
B7931028: Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care. Lead: Dianne Morales
BMS-IM1121/SLE: An Investigational Study to Evaluate BMS-986165 in Patients with Systemic Lupus Erythematosus. Lead: Gretchen Pifer
GSK-20190: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate. Lead: Judy Lara
GSK-20218: Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors. Lead: Judy Lara
KZR 606-202/INC/SLE: A Study of KZR-616 in Patients with Systemic Lupus Erythematosus with and without Nephritis.Lead: Gretchen Pifer
PA0010: A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL). Lead: Marisabel Collado
PA0011: A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects with Active Psoriatic Arthritis (BE COMPLETE). Lead: Marisabel Collado
TV48125: A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia. Lead: Nyasha McLean